Hard to Treat Diseases Inc. (HTDS)

OTCMKTS · Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
At close: Aug 15, 2025
Market Cap5.82K
Revenue (ttm)6.16M
Net Income (ttm)974.30K
Shares Out5.82B
EPS (ttm)0.00
PE Ratio0.01
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,000
Average Volume860,587
Open0.0000
Previous Closen/a
Day's Range0.0000 - 0.0000
52-Week Rangen/a
Beta-1.93
RSI51.46
Earnings Daten/a

About Hard to Treat Diseases

Hard to Treat Diseases Inc. manufactures, supplies, and exports biopharmaceuticals and vaccines in China and internationally. The company offers biologicals, including reteplase (rPA), mycobacterium vaccae, acutobin urinary kallidinogenase, ulinastatin, and cerebroprotein hydrolysate for injection; chemicals, such as cobratide injection, entecavir capsule, HES, dasatinib tablets, thymosin a1 for injection, imipenem and cilastatin sodium for injection, and meropenem for injection; and vaccines, which include rabies vaccine, ACYW135 meningococcal... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Country United States
Stock Exchange OTCMKTS
Ticker Symbol HTDS
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.